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Abstract
Background: Neuronal accumulation of misfolded microtubule-associated protein tau is a hallmark of
neuropathology in Alzheimer’s disease, frontotemporal dementia, and other tauopathies, and has been a
therapeutic target. Microglia can spread tau pathology by secreting tau-containing exosomes, although the specific
molecular target is yet to be identified for the therapeutic intervention. P2X purinoceptor 7 (P2RX7) is an ATP-gated
cation channel, enriched in microglia and triggers exosome secretion. The purpose of the study is to examine the
therapeutic effect of an orally applicable, CNS-penetrant P2RX7 specific inhibitor on the early disease stage of a
tauopathy mouse model.
Methods: Three-months-old P301S tau mice were treated with P2RX7-specific inhibitor GSK1482160 or vehicle for
30 days, followed by behavioral, biochemical and immunohistochemical assessment. GSK1482160 was also tested
for exosome secretion from primary cultured murine astrocytes, neurons and microglia in vitro.
Results: Oral administration of GSK1482160 significantly reduced accumulation of MC1+ and Alz50+ misfolded tau
in hippocampal regions, which was accompanied with reduced accumulation of Tsg101, an exosome marker, in
hippocampal neurons. Proximity ligation assay demonstrated complex formation of Alz50+ tau and Tsg101 in
hippocampal neurons, which was reduced by GSK1482160. On the other hand, GSK1482160 had no effect on
microglial ramification or CD68 expression, which was significantly enhanced in P301S mice, or pro/anti-
inflammatory cytokine gene expression. Strikingly, GSK1482160-treated P301S mice show significantly improved
working and contextual memory as determined by Y-maze and fear conditioning tests. GSK1482160 also
significantly increased accumulation of Tsg101 and CD81 in microglia in vivo, suggesting its suppression of P2RX7-
induced exosome secretion from microglia. This effect was confirmed in vitro, as ATP-induced secretion of tau-
containing exosome was significantly suppressed by GSK1482160 treatment from primary murine microglia, but
not from neurons or astrocytes.
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Discussion: The oral administration of P2RX7 inhibition mitigates disease phenotypes in P301S mice, likely by
suppressing release of microglial exosomes. P2RX7 could be a novel therapeutic target for the early stage
tauopathy development.
Keywords: Alzheimer’s disease, Exosome, Extracellular vesicles, Microglia, Microtubule-associated protein tau, P2X
purinoceptor 7, Tauopathy
Background
Neurofibrillary tangles, primarily composed of intracellu-
lar aggregates of hyperphosphorylated microtubule-
associated protein tau (tau), are a pathological hallmark
in Alzheimer’s disease (AD) and known to progress from
the entorhinal cortex (EC) to the hippocampal regions
in the early stage of AD. The precise mechanism under-
pinning this spread is yet to be elucidated, and there has
been no successful drug to halt tau pathology progres-
sion in the early stages of AD.
Microglia, the innate immune cells in the central
nervous system (CNS), play a pivotal role in spreading
tau by releasing exosomes, small extracellular vesicles
(EVs: 50–150 nm), which contain and transfer patho-
logical tau in the tauopathy mouse model [1]. Other
groups demonstrated that exosomes isolated from a dif-
ferent tau mouse model can spread tau pathology after
intracranial injection into the recipient mice [2] and
AD-associated BIN1 is critical in microglia-mediated
spread of tau pathology via exosome secretion [3]. These
evidences support the idea that targeting specific mole-
cules to suppress exosome secretion from microglia may
lead to halt tau propagation. Among many possible mol-
ecules regulating exosome release, we focused on P2X
purinoceptor 7 (P2RX7), an ATP-evoked Na+/Ca2+
channel predominantly expressed in microglia [4]. Puri-
nergic receptors have important multifaceted properties
in the CNS; they not only contribute to neurotransmis-
sion and neuromodulation but also to the ATP-driven
chemotactic response [5, 6]. Previous studies have shown
increased expression of P2RX7 near amyloid-β (Aβ)
plaques in the brains of AD patients and AD animal
models [7, 8], suggesting a role of P2RX7 in disease pro-
gression. Activation of P2RX7 has been shown to trigger
Na+/Ca2+ influx, plasma membrane depolarization, se-
cretion of EVs, chemotaxis and activation of inflamma-
somes [9]. Pharmacologic inhibition or genetic deletion
of P2rx7 in rodents could alter the exosome release from
macrophages and other myeloid cells [10–12]. However,
the role of P2RX7 has never been examined in the con-
text of tau spread through exosome secretion in tauopa-
thy animal models.
GSK1482160 is an orally applicable and CNS-penetrant
selective antagonist of P2RX7, and has been successfully
clinically tested in phase I study [13, 14]. Here, we have
comprehensively tested the therapeutic effect of
GSK1482160 in P301S tau mouse model [15] by behavioral
tests, biochemistry and neuropathology. We discovered that
GSK1482160 treatment reduced accumulation of misfolded
tau and restored cognitive function in P301S mice, likely
via suppressing exosome secretion. Furthermore, we vali-
dated the predominant effects of GSK1482160 on exosome
secretion from microglia in vitro.
Materials and methods
Note: Methods and any associated references are
available in the online version of the paper.
Results
Pharmacological blockade of P2RX7 decreases
accumulation of misfolded tau aggregates in P301S
mouse brain
To determine the effect of pharmacological blockade
of P2RX7 on tau pathology development in P301S
mice, we performed immunohistochemistry (IHC)
and biochemical analysis of tau pathology after
GSK1482160 or vehicle administration from 3
months of age for 30 days. There was no significant
change in body weight during the treatment period
among groups (Supplementary Fig. 1A). We first ex-
amined the effect of GSK1482160 treatment on tau
accumulation in P301S mice. The total human tau
levels in the hippocampus and cortex were un-
changed between P301S mice with treatments, show-
ing that GSK1482160 treatment has no effect on
P301S tau transgene expression (Supplemental
Table 1 and 2). Interestingly, pSer199 tau levels were
significantly reduced by GSK1482160 treatment in
the hippocampal but not the cortical regions of
P301S mice (Supplemental Table 1 and 2). In con-
trast, pT181 and pT231 tau levels were unchanged
in both regions of P301S mice between the two
treatment groups. Alz50 and MC1 are two of the
earliest markers of the misfolded tau [16, 17] and
detect AD-specific epitopes formed by two discon-
tinuous portions of tau: 313VDLSKVTSKC322 and
7EFE9 [18, 19]. Importantly, the level of Alz50 and
MC1 reactivity correlates with the severity and
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progression of AD [19]. Alz50 immunoreactivity in
vehicle-treated P301S group was significantly ele-
vated in both pyramidal cell bodies and neuropils of
the Cornus Ammonis (CA)1, CA3, hilus, granular
cell layer (GCL) of dentate gyrus (DG), and entorhi-
nal cortex (EC) layer II compared to wild-type (WT)
group (Fig. 1a-b, red columns), consistent with pre-
vious findings [20]. Strikingly, GSK1482160
Fig. 1 GSK1482160 treatment reduced accumulation of misfolded tau in P301S mouse brain. a-b. Alz50 staining (a) and quantification (b) in the
hippocampal and cortical regions of mice ± GSK1482160 treatment. c-d. MC1 staining (c) and quantification (d) in the stratum radiatum of CA1
and mossy fibers of CA3 of the hippocampal regions. b, d: ***p < 0.001 and ****p < 0.0001 compared with WT + VEH group; #p < 0.05 and ##p < 0.01
compared with P301S + VEH group; n.s denotes no significance as determined by one-way ANOVA (alpha = 0.05) and Dunnett’s post-hoc. n = (6, 7,
7) mice for WT + VEH, P301S + VEH and P301S + GSK groups. Graphs indicate mean ± s.e.m.
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treatment significantly decreased Alz50 immunoreac-
tivity in these regions (Fig. 1a-b, blue columns). We
observed similar findings by MC1 staining: MC1+
misfolded tau was prominently enriched in the
stratum radiatum of CA1 and mossy fibers of CA3
in vehicle-treated P301S group, which was signifi-
cantly reduced by GSK1482160 treatment (Fig. 1c-d).
These data demonstrate that misfolded tau accumu-
lates in the neuronal cell body and dendrites of hip-
pocampal and EC regions of P301S mice at 4.5
months of age, which was suppressed by
GSK1482160 administration.
Pharmacological blockade of P2RX7 reduces Tsg101+
immunoreactivity in P301S tau mice
Exosomes mediate trans-cellular communication in the
CNS, including neuron-microglia interaction in health
and disease [21, 22]. To determine how P2RX7 regu-
lates secretion of exosomes, we performed IHC against
tumor susceptibility gene 101 (Tsg101), a specific
marker of ESCRT-I involved in exosome synthesis.
Tsg101 immunoreactivity was higher in the GCL of
DG, CA1 and CA3 regions of the hippocampus and EC
layer II in vehicle-treated P301S group compared to
WT group (Fig. 2a-b). Remarkably, GSK1482160 treat-
ment suppressed Tsg101 accumulation in the CA1,
GCL and EC layer II in P301S mice (Fig. 2a-b). The re-
duction in Tsg101 accumulation was not due to the
neuronal cell loss, because there were still comparable
numbers of NeuN+ neurons in the hippocampal region
of P301S mice at this age (Supplementary Fig. 1B).
Together, these results show that Tsg101+ exosomes or
intraluminal vesicles (ILVs) are significantly accumu-
lated in hippocampal and EC neurons in P301S mice,
which is partially reversed by GSK1482160 treatment.
Concomitant reduction in tau aggregation may suggest
the role of exosomes as vehicles of tau between the
specific brain regions.
Association of misfolded tau with Tsg101 in P301S mouse
brain
To determine whether these tau aggregates were
sorted in exosomal cargo to be migrated in the hip-
pocampal region, we examined the co-localization
and correlation of Alz50 and exosome component by
laser-scanning confocal microcopy. Exosomal cargo
proteins are recruited by the exosome-specific ESCR
T-I component Tsg101 [12]. We observed partial co-
localization of Alz50 and Tsg101 in the CA1 and
CA3 regions in vehicle-treated P301S mice, which is
diminished by GSK1482160 treatment (Fig. 3a-b).
The scattered plot analysis shows the close associ-
ation of the amount of Alz50 and Tsg101 in CA1 and
CA3 regions unexpectedly only in GSK1482160-
treated group (Fig. 3c-d). This suggests that suppres-
sion of EV-dependent tau release by the drug treat-
ment contained Alz50+ tau in Tsg101+ area in these
regions (Fig. 3c-d). The lack of association in vehicle-
treated group implicates that Alz50+ tau signal, al-
though upregulated in CA1 and CA3 regions of this
group, are released from EVs after being transferred
from microglia in these areas. This approach has
some limitation in quantifying the EV-mediated tau
transport. Thus, we examined whether Tsg101+
immunopuncta is in close proximity to Alz50+ mis-
folded tau using the proximity ligation assay (PLA)
representing their close association (close proximity
20–50 nm) [23] (Fig. 3e). We quantified the number of
PLA+ Tsg101/Alz50 complex in CA1 and CA3 regions,
which are significantly reduced by GSK1482160 treat-
ment compared to vehicle-treated P301S mice (Fig. 3f-
g). It has been reported that the ESCRT-0 component
hepatocyte growth factor-regulated tyrosine kinase
substrate (Hgs) is also required for exosome formation
and/or secretion [24]. Hgs was also in close proximity
to Alz50 as determined by Hgs/Alz50 PLA, which was
reduced by GSK1482160 treatment (Supplementary
Fig. 2A-B). Taken together, these data indicate that in-
creased number of Alz50+ misfolded tau associated
with Tsg101+ exosomes or ILVs in the hippocampal
region, which was suppressed by GSK1482160, sug-
gesting that P2RX7 regulates pathological tau transfer
to hippocampal neurons via exosomes.
Pharmacological blockade of P2RX7 rescues cognitive
deficits in Y maze, pre-pulse inhibition and contextual
fear conditioning of P301S mice
To determine the effect of P2RX7 inhibition on
cognitive function, we performed batteries of the be-
havioral assays with vehicle or GSK1482160-treated
P301S mice (Fig. 4a). The Y-maze test was performed
to evaluate spatial working memory at 4 months of age
(Fig. 4b). Vehicle-treated P301S mice showed a signifi-
cant decrease in alternations compared to age-
matched WT mice, which was rescued by
GSK1482160 treatment (Fig. 4c). There was no differ-
ence in the total number of entries into each arm and
total distance moved among the three groups, suggest-
ing that spontaneous motor activity was unaffected by
P301S tau transgene expression or drug treatment at
this age (Fig. 4d-e). A pre-pulse inhibition (PPI) test is
widely used to measure deficits in information-
processing abilities or sensorimotor gating across spe-
cies, including humans and rodents [25]. There were
no significant differences in startle response among
groups at baseline (Fig. 4f-g). Interestingly, the % PPI,
an index of sensorimotor gating, was significantly
lower in P301S mice at 3db and 12 db (Fig. 4h)
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compared to that in WT mice (main effect p =
0.0074) while GSK1482160 treated-P301S mice
showed recovery of %PPI at 6db compared to ve-
hicle treated P301S mice (treatment effect p =
0.0206). We next performed the fear-conditioning
test, assessing the spatial memory ability in WT
and P301S mice with or without GSK1482160 treat-
ment (Fig. 4i). We observed significant deficits in
fear memory acquisition in vehicle treated P301S
compared to WT mice, which was not recovered by
GSK1482160 treatment (Fig. 4j). We then tested
their contextual fear memory 24 h later, which is
largely dependent on hippocampal function. Inter-
estingly, we observed significantly higher contextual
freezing in GSK1482160 treated P301S mice
compared to that of vehicle treated P301S mice
(Fig. 4k), suggesting treatment effect of P2RX7 in-
hibition on hippocampal memory. These results
demonstrate that GSK1482160 treatment on P301S
mice ameliorates impairment in working memory in
Y-maze, information-processing ability in PPI tests
and contextual memory in fear-conditioning test.
GSK1482160 administration induces exosome
accumulation in microglia in P301S mice
We previously reported that depletion of microglia
or inhibition of exosome synthesis suppressed accu-
mulation of tau in the hippocampus in this mouse
model [1]. Thus, the reduction of tau pathology and
recovery of cognitive function by GSK1482160
treatment on P301S mice could be mediated by
suppressing microglial exosome secretion. To
Fig. 2 GSK1482160 treatment reduced Tsg101+ immunoreactivity in P301S mouse brain. a. Tsg101 staining (green) in the hippocampus and
cortex of mice ± GSK1482160 treatment, DG: dental gyrus; CA1 and CA3 of hippocampus; EC II: entorhinal cortex layer II. Scale bars = 200, 50, 20,
20 and 50 μm (left to right). b. Quantification of Tsg101 fluorescent intensity. *p < 0.05 and **p < 0.01 compared with WT + VEH group; #p < 0.05
and ##p < 0.01 compared with P301S + VEH group; n.s denotes no significance as determined by one-way ANOVA (alpha = 0.05) and Dunnett’s
post-hoc. n = (6, 7, 7) mice for WT + VEH, P301S + VEH and P301S + GSK group. Graphs indicate mean ± s.e.m.
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determine the effect of GSK1482160 treatment on
microglial exosome efflux, we performed immuno-
fluorescence against Iba-1 and Tsg101 or CD81, an-
other exosomal marker and tetraspanin superfamily
member predominantly expressed on the plasma
membrane (Fig. 5a-b). Interestingly, we found sig-
nificantly increased signal of Tsg101 in microglia in
GSK1482160-treated P301S mice compared to the
vehicle-treated P301S mice, suggesting that
GSK1482160 treatment accumulated Tsg101+ ILVs
by inhibition of their secretion from microglia (Fig.
5a and c left). There was no difference in Tsg101
immunoreactivity in microglia between the vehicle-
treated P301S and WT groups. In contrast to this
finding in microglia, Tsg101 immunoreactivity in
astrocytes, oligodendrocytes or neurons was not en-
hanced by GSK1482160 treatment (Supplemental
Fig. 3A-C). Furthermore, immunoreactivity of CD81
was also increased in microglia in the mouse brain
treated by the GSK1482160 (Fig. 5b and c right).
Following the assessment of 3D surface rendering
reconstruction images of CD81 in microglia by
Imaris software, most of CD81 signal was bound to
the inner plasma membrane of microglial processes
(Fig. 5d), suggesting the retention of ILVs by
GSK1482160. In order to determine whether
GSK1482160 treatment affects the microglia pheno-
type and cytokine secretion profile, we performed
microglia morphology analysis and examined the
expression level of Il6, Il10, Tgfb1, Il1a, Il1b, Il18,
Ifng and Tnfa by qRT-PCR. Immunofluorescence
against Iba-1 and purinergic receptor P2Y12
(P2ry12), a specific and representative marker of
resident microglia, did not show a change in micro-
glia population among 3 groups (Supplementary
Fig. 4A-B). Microglial morphology analysis using
Iba-1 stained images and Imaris software revealed
that P301S mice significantly had longer processes
and higher branches with more intersections com-
pared to WT, which change was not normalized by
GSK1482160 treatment (Supplementary Fig. 4 C-E).
The production of pro- and anti-inflammatory cyto-
kines were not changed among 3 groups except 3-
fold higher expression level of Tnfa in P301S
mouse, which was not normalized by GSK1482160
treatment (Supplemental Fig. 4F). Finally, we evalu-
ated if GSK1482160 treatment affect microglial
phagocytic function by immunofluorescence against
CD68, a marker for phagocytic myeloid cells. Al-
though there was an increase in the number of
CD68+ microglia in P301S mice compared to WT
mice, GSK1482160 treatment did not show any ef-
fect (Supplemental Fig. 5A-C). This is consistent
with a previous study showing that P2X7R defi-
ciency did not modify the microglial numbers, cyto-
kine secretion profile, or phagocytic activity while it
reduced Aβ deposition, rescued cognitive deficits
and improved synaptic plasticity in APPPS1 mice
[26]. Together, these results suggested that the ef-
fect of GSK1482160 on tau pathology in P301S
mice is mediated by suppressed exosome secretion
from microglia, which is independent of microglial
morphology or phagocytic function.
Pharmacological blockade of P2RX7 suppresses EV
secretion by microglia in vitro
P2RX7 is predominantly present in microglia in cen-
tral nervous system, although a limited amount may
still be expressed in neuron and astrocyte [27]. To
determine which cell type is mainly affected by
GSK1482160 for secretion of tau and exosomes, we
tested primary cultured microglia, neurons and as-
trocytes followed by GSK1482160 treatment as previ-
ously described [1]. Microglia were isolated from
WT P0 pups and pre-incubated with aggregated hu-
man tau for 24 h before GSK1482160 treatment ran-
ging from 0.1–100 μM and induction of exosome
secretion by LPS and ATP (Fig. 5e). Since P301S
mice express mutant tau mostly in neurons followed
by astrocytes and not in microglia [28], and our pre-
vious study show very limited amount of hTau
phagocytosis by these cell types [1], we examined
(See figure on previous page.)
Fig. 3 Co-localization and correlation of Alz50 and Tsg101 immunoreactivity in P301S mouse brain. a, b. Laser-scanning confocal microscopic
imaging of Tsg101 and Alz50 staining in the CA1 (a) and CA3 (b) hippocampal region. c, d. Scattered plot for the Pearson’s correlation analysis of
Alz50 and Tsg101 signal for CA1 (c) and CA3 regions (d), respectively. Each dot represents an individual animal from P301S + VEH group (red) and
P301S + GSK1482160 group (blue). e. Schematic diagram of PLA, only occurs when proteins are in close proximity (20–50 nm). f. Representative
laser-scanning confocal microscopic images of PLA signals between Tsg101 and Alz50 (red) with Dapi (blue) at CA1 and CA3 of the
hippocampus. g. Quantification of the PLA+ immunopuncta for Tsg101-Alz50 at CA1 and CA3 hippocampal regions. ***p <0.001, ****p < 0.0001
compared with WT + VEH group; #p < 0.05 and ##p < 0.01, compared with P301S + VEH group; n.s denotes no significance as determined by one-
way ANOVA (alpha = 0.05) and Dunnett’s post-hoc. n = (4, 4, 4) mice for WT + VEH, P301S + VEH and P301S + GSK groups. Graphs
indicate mean ± s.e.m.
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the effect of GSK1482160 treatment on hTau se-
cretion from neurons and astrocytes isolated from
E16 P301S embryonic brains. The cells were
treated with ATP, and the EV-enriched fractions
were isolated from the ATP-treated conditioned
media by sequential centrifugations. Nanoparticle
tracking analysis (NTA) revealed that ATP stimu-
lation significantly increased EV secretion from
microglia in the exosomal range (50–150 nm) (Fig.
5f). Notably, pre-treatment with GSK1482160 sig-
nificantly suppressed exosome secretion from
microglia in a dose-dependent manner (Fig. 5f).
We also obtained similar results using microglial
cell line BV-2 (Supplementary Fig. 6A-C). The
dose-dependent suppression of exosome secretion
by GSK1482160 treatment was further confirmed
by ELISA-based quantification of exosome-specific
marker CD9 (Fig. 5g). In accord, hTau level in EVs
secreted from hTau-phagocytosed and ATP-
stimulated microglia was significantly reduced by
GSK1482160 pre-treatment at 10 μM (Fig. 5h left).
There was no change in hTau in microglia cell ly-
sates by the GSK1482160 pre-treatment (Fig. 5h
right). EVs and tau secretion from P301S mouse-
derived neurons and astrocytes were also tested in
the same manner. Although ATP stimulation sig-
nificantly increased EV secretion from neurons or
astrocytes, there was no significant effect of
GSK1482160 pre-treatment on EV secretion from
either cell types (Fig. 5i-j). Tau secretion was de-
tected in the EV of ATP-stimulated neurons and
astrocytes to a lesser extent comparing to the
amount of Tau (close to 1500 pg/mL) secreted
from microglia, but these were not inhibited by
GSK1482160 pre-treatment (Fig. 5i-j). These data
suggest that EV secretion is inducible from neu-
rons or astrocytes by ATP stimulation, but it is in-
sensitive to P2RX7 inhibition. Together, these
results indicate that GSK1482160 significantly
suppresses exosome and tau secretion from hTau-
phagocytosed microglia but not from neurons or
astrocytes.
Discussion
In the present study, we have demonstrated that
pharmacologic blockade of P2RX7 at an early stage
in P301S mice significantly decreased tau accumula-
tion in the hippocampal and EC regions and ame-
liorated hippocampal memory deficits. Meanwhile,
there was strong correlation between the accumula-
tion of exosomal marker Tsg101 and the misfolded
tau marker (Alz50) in the hippocampal region of
P301S mice. In addition, the ATP-induced secretion
of exosomes from murine microglia was signifi-
cantly suppressed by the P2RX7 inhibitor, whereas
it had no effect on tau or EV secretion from
primary murine neurons or astrocytes in vitro.
Taken together, these findings establish a functional
role of P2RX7 on microglial exosome secretion in
tau pathology progression, and would serve as
promising preclinical data for the development of
P2RX7 inhibitors as potential therapeutics of AD
(summarized in Fig. 6). Moreover, P2RX7 deficiency
decreased Aβ load and also rescued cognitive defi-
cits in APP/PS1 mice [26]. Thus, P2RX7 may be a
beneficial target for suppressing both Aβ accumula-
tion and tauopathy development in AD.
The P301S mouse model recapitulates not only tau
pathology but also neurological deficits of human tauo-
pathies with dementia including AD at the early stage
[15]. Moreover, behavioral abnormalities shown by Y-
maze, PPI and contextual fear conditioning tests have
widely been used to recapitulate human cognitive disor-
ders found in AD, especially hippocampal spatial learn-
ing disturbances [29–31]. In the present study, we found
spatial learning deficits in P301S mice and its rescue by
GSK1482160 treatment. Although behavior deficits in
PPI test is a common finding in AD mouse models in-
cluding rTg4510, N279K and R406W tau models [32–
34], a study showed enhanced PPI in P301S mice relative
(See figure on previous page.)
Fig. 4 Behavioral testing of P301S mice after GSK1482160 treatment. a. Schematic diagram of behavioral tests. b-e. Schematic diagram of Y-maze
(b). Percentage of spontaneous alternation (c), number of total arm entries (d) and total distance moved during tests (e) in Y-maze. *p < 0.05,
P301S + VEH vs. WT + VEH; #p < 0.05, P301S + GSK vs. P301S + VEH as determined by one-way ANOVA (alpha = 0.05) with Dunnett’s post-hoc.
n = (17, 21, 20) mice for WT + VEH, P301S + VEH and P301S + GSK groups. Graphs indicate mean ± s.e.m. f and g. Schematic diagram of pre-pulse
inhibition test (f). Acoustic startle amplitude as measured in trials with 120 db without a pre-pulse (g). PPI (%) at three different pre-pulse
intensities (3, 6 and 12 db above 65db background) (H). *p < 0.05, **p < 0.01, P301S + VEH vs. WT + VEH; #p < 0.05, P301S + GSK vs. P301S + VEH, n.s
denotes no significance, as determined by two-way ANOVA (alpha = 0.05) and Bonferroni’s post-hoc. n = (17, 21, 20) mice for WT + VEH, P301S +
VEH and P301S + GSK groups. i-k. Schematic diagram of fear conditioning (i). j. Percentage of freezing time of each minute during cued fear
acquisition. ****p < 0.0001, P301S + VEH vs. WT + VEH as determined by two-way ANOVA (alpha = 0.05) and Bonferroni’s post-hoc. n = (17, 21, 20)
mice for WT, P301S + VEH and P301S + GSK groups. k. % freezing during contextual text. ***p < 0.001, P301S + VEH vs. WT + VEH; ##p < 0.01,
P301S + GSK vs. P301S + VEH as determined by paired Student’s t-test at each minute during the 5 min period. Graphs indicate mean ± s.e.m.
Ruan et al. Molecular Neurodegeneration           (2020) 15:47 Page 9 of 14
Fig. 5 (See legend on next page.)
Ruan et al. Molecular Neurodegeneration           (2020) 15:47 Page 10 of 14
to WT controls at 6 months of age [15]. This could be
due to the strain background differences which could
affect the behavior of the animals. While they used mice
with a C57BL/6 J background, ours were from the
B6C3H/F1 background, and will require future experi-
ments for validation.
Although P2RX7 is predominantly expressed in
microglia, it is also expressed in oligodendrocytes in
the CNS [4] and in astrocytes under inflammatory
conditions in P301S mice [35]. Several groups re-
ported the presence of tau in neuron-derived exo-
somes isolated from the blood and cerebrospinal
fluid (CSF) in AD patients [36]. Thus, reduction of
tau aggregates and Tsg101 immunoreactivity by
GSK1482160 may also reflect the direct effect of
P2RX7 inhibition on different cell types expressing
P2RX7 in vivo [37]. P2RX7 inhibition did not in-
crease Tsg101 expression in neurons, astrocytes or
oligodendrocytes but exclusively in microglia
in vivo and in vitro, therefore microglia may be the
major source of Tsg101 bound aggregated tau. To
determine if P2RX7 is involved in tau-containing
EV secretion from these cells, cell type-specific de-
letion of P2RX7 in tau propagation mouse models
would be helpful as a future study.
In addition to exosomes, larger EVs (ectosomes/micro-
vesicles) may also contain abnormally phosphorylated
tau [38]. ATP-induced P2RX7 stimulation induced shed-
ding of ectosomes/microvesicles as well as secretion of
exosomes [39, 40]. Further investigation is needed to
determine the involvement of larger EVs to understand
their roles on tau transfer and AD pathobiology. In
terms of tau pathology, we found that the hippocampal
CA1 region was the most sensitive to a reduction of tau
aggregates in the hippocampal region by GSK1482160,
which was correlated with a reduction in Tsg101 immu-
noreactivity. Physical proximity of tau and exosomes was
further confirmed by PLA between Alz50 and Tsg101 or
Hgs, the ESCRT-0 molecule. These data suggest that
exosomal tau transfer may occur in a region-specific
manner in P301S mice.
Trans-neuronal propagation of tau aggregates be-
tween anatomically connected brain regions was
first reported by Braak [41]. Free form tau can be
transferred as a monomer or oligomers by endo-
cytosis or macropinocytosis and induce templated
conformational changes in the recipient endogenous
tau [42]. Recent studies indicate low density lipo-
protein receptor-like proteins or heparan sulfate
proteoglycan as the molecular mechanisms by
which tau protein is transferred [42, 43]. While tau
is the principle molecular component in tau path-
ology, there are considerable evidences to support
the roles of extrinsic factors in tau transfer. We
have previously reported that EV-associated tau se-
creted from microglia play a critical role on tau
propagation in AAV tau propagation- and P301S
mouse model [1]. Our recent study revealed the in-
flammatory alternation of EV cargo composition re-
leased from human primary cultured astrocytes: IL-
1β stimulation enhances the EV cargo load of integ-
rins, which facilitate their uptake by neurons, sug-
gesting the high transmissibility of glial EVs under
inflammatory conditions [44]. BIN1, the second
most significant AD genome-wide association study
(GWAS) gene, is present in EVs in the AD CSF,
forms complexes with tau and enhances EV secre-
tion [3]. Strikingly, microglia-specific deletion of
Bin1 suppresses tau propagation in P301S mice [3].
Conversely, virus-mediated over-expression of BIN1
accelerated tau pathology in P301S mouse brains
[45]. These studies suggest the potential contribu-
tion of the AD GWAS genes on EV-mediated tau
propagation.
(See figure on previous page.)
Fig. 5 GSK1482160 treatment induced exosomal accumulation in microglia in P301S mice in vivo and suppressed microglial EV secretion in vitro.
a-b. Immunofluorescence images of mouse hippocampal CA1 regions captured by the laser-scanning confocal microscopy. Iba-1 (green) co-
stained with Tsg101 (red, left panel) and CD81 (red, right panel). c. Quantitative analysis of Tsg101 and CD81 florescent intensity in Iba-1+ positive
cells: ***p < 0.001, ****p < 0.0001, P301S + GSK compared with P301S + VEH group, n.s denotes no significance as determined by one-way ANOVA
(alpha = 0.05) and Dunnett’s post-hoc. Each dot represents an individual cell, Tsg101: n = (15, 13, 13) and CD81: n = (25, 32, 32) for (WT + VEH,
P301S + VEH, P301S + GSK1482160) from 5 to 7 animals per group. Graphs indicate mean ± s.e.m. d. Re-constructed structure of exosome in
microglia by Imaris software from P301S + GSK1482160 group. Membrane bound CD81(red) is shown in microglial processes (green). Scale bar 5,
5 and 2 μm. e. Scheme of EV isolation protocol from primary culture microglia, astrocyte and neuron conditioned media, followed by NTA of
isolated EVs. Microglia were stimulated by LPS and ATP. All of the cells were pretreated by GSK1482160 or vehicle. f-h. EVs were isolated from the
culture media of primary microglia without stimulation of ATP (control) or stimulated by 5 mM ATP and treated by either vehicle or GSK1482160
(0.1-100 μM). NTA plot of mode size and concentration (F left), particle numbers (f right), and CD9 ELISA (g) of microglial EVs. Total tau ELISA for
the EV fraction and cell lysate from microglia pretreated with the vehicle or 10 μM of GSK1482160 (h). i-j. NTA and tau ELISA of isolated EVs from
primary astrocyte (i) and neuron (j). *p < 0.05, **p < 0.01 and ***p < 0.001 compared with Control group; #p < 0.05 and ##p < 0.01 compared with
ATP-treated group; n.s denotes no significance as determined by one-way ANOVA (alpha = 0.05) and Dunnett’s post-hoc; Student’s t-test for the
total tau ELISA. Data are representative of at least three independent experiments. Graphs indicate mean ± s.e.m.
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Conclusions
In summary, our study demonstrated that pharmaco-
logical block of P2RX7 in P301S mice significantly de-
creased tau accumulation in the hippocampal and EC
regions, and ameliorated hippocampal memory deficits
as determined by several behavioral tests. The misfolded
tau marker shows co-localization with exosome markers
in the affected brain regions, and our in vitro study
shows cell type-specific suppression of exosome release
by the P2RX7 inhibitor. These findings shed light on the
specific P2RX7 blockers as novel disease-modifying
agents for AD.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13024-020-00396-2.
Additional file 1: Supplementary Fig. S1. No difference in body
weight and neuron number after GSK1482160 administration. A. Body
weight of animals during the period of oral gavage of GSK1482160 (GSK)
or vehicle (VEH) twice per day. B. Neuron-specific expression of NeuN
staining in the hippocampus of P301S with GSK1482160 or vehicle treat-
ment. There was no change in the neuron number between two groups.
Original images were captured at mouse brain hippocampus by using
20× objective.
Additional file 2: Supplementary Fig. S2. PLA signals between Alz50
and Tsg/Hgs in hippocampus. A. Epi-fluorescence microscopic images of
Tsg101 and Alz50 staining in the DG, CA1 and CA3 of hippocampal
region of P301S mice ± GSK1482160 treatment and wild-type mice. Ori-
ginal images were captured at 20× objective. B. Representative laser-
scanning confocal microscopic images of PLA signals between Hgs and
Alz50 at CA1 and CA3 of hippocampus (red) with Dapi counterstaining
for nucleus (blue). Original images were captured at 63× oil immersion
objective.
Additional file 3: Supplementary Fig. S3. Tsg101 immunoreactivity in
astrocyte, oligodendrocytes, or neurons in CNS with or without
GSK1482160 treatment. A. Astrocyte (GFAP, green) co-stained with
Tsg101 (red). B. Oligodendrocyte (MOG, green) co-stained with Tsg101
(red). C. Neuron (MAP 2, green) co-stained with Tsg101(red). 4 animals
were stained per group. Original images were captured at CA1 region of
mouse brain hippocampal field by using 40× oil immersion objective
(Leica SP8 Lightning confocal microscopy).
Additional file 4: Supplementary Fig. S4. GSK1482160 has no effect
on microglia morphology and inflammatory cytokine production. A-B.
Microglia stained with Iba-1 (gray scale) and P2ry12 antibodies (green, A)
and their quantification (B). Each dot represents an individual animal, 5–6
animals per group. n.s denotes no significance as determined by one-
way ANOVA (alpha = 0.05) and Dunnett’s post hoc. Graphs indicate
mean ± s.e.m. C-E: Morphological analysis of microglial processes stained
with Iba-1 by Imaris software. Representative image of microglial process
(C), quantification of average process length and branch points (D), ***p <
0.001, one-way ANOVA with Dunnett’s post hoc, and Sholl intersections
analysis (E), ****p < 0.0001, two-way ANOVA with Bonferroni’s post hoc;
each dot represents an individual cell, n = (22, 35, 38) for (WT + VEH,
P301S + VEH, P301S + GSK1482160) from 5 animals per group. F. The
mRNA expression level of pro- and anti-inflammatory cytokine among
three groups. *p < 0.05, one-way ANOVA with Dunnett’s post hoc, 5–6 an-
imals per group.
Additional file 5: Supplementary Fig. S5. Effect of GSK1482160 on
tau pathology was independent of phagocytosis activity of microglia. A
Fig. 6 Scheme of the potential mechanisms underlying the reduction of tau pathology via targeting microglial P2RX7 in tau transgenic mouse
model. a. Tau aggregates may spread trans-synaptically if the synapses are intact. However, in case of tau accumulation, synapses are inactivated
and subjected to microglial sensing and pruning in disease conditions. Phagocytosed synapses contain tau aggregates, which will be transported
through endosomal pathways, and many of them will be digested through the endolysosomal pathway. In parallel, tau aggregates in the late
endosome will be incorporated into the ILVs of MVBs, which will be secreted as exosomes and propagated into nearby neurons. P2RX7 mediates
secretion of both exosomes and microvesicles. b. Inhibition of P2RX7, mainly expressed in microglia, reduces secretion of EVs and potentially
enhances intracellular clearance of tau through endolysosomal degradation, suppressing the microglia-mediated tau propagation in P301S mice
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and B. Microglia phagocytic function analysis. Microglia (Iba-1, green) co-
stained with a lysosome marker CD68 (red) (A); Quantification of the
%CD68+ area in Iba-1+ microglia (B), **p < 0.01, one-way ANOVA with
Dunnett’s post hoc, each dot represents an individual cell, n = (61, 59, 61)
for (WT + VEH, P301S + VEH, P301S + GSK1482160) from 5 animals per
group. C. 3D surface rendering of CD68+ area in microglia from P301S +
GSK142160 group by Imaris software.
Additional file 6: Supplementary Fig. S6. GSK148620 treatment
suppress exosomal secretion from murine microglial-like BV2 cells. A.
Scheme of EV isolation protocol from murine microglial cell line BV-2
conditioned media after ATP stimulation. B-C. NTA analysis of isolated
EVs. ***p < 0.001, compared with Control group; #p < 0.05, ##p < 0.01 and
###p < 0.01, compared with Vehicle-treated group; n.s denotes no signifi-
cance as determined by one-way ANOVA (alpha = 0.05) and Dunnett’s
post-hoc. Graphs indicate mean ± s.e.m.
Additional file 7: Supplementary Table 1. GSK1482160 did not
change the total Tau expression in P301S mouse brain hippocampus, but
slightly reduced the hyperphosphorylation level of Tau. Supplementary
Table 2. GSK1482160 did not change the total Tau expression and
hyperphosphorylation level in P301S mouse cerebral cortex.
Additional file 8. Supplementary Methods Materials and Methods.
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